3/7/2023 12:46:14 PM - Consolidating near its 50 DMA line ($81.29) since a noted gap down on 2/28/23 for a big volume-driven loss, retreating from near its 52-week high. Reported Dec '22 quarterly earnings -27% on +14% sales revenues versus the year ago period. Prior quarterly earnings increases have not been strong and steady above the +25% minimum guideline (C criteria).
3/2/2023 1:03:42 PM - Held its ground above its 50 DMA line since a noted gap down on 2/28/23 for a big volume-driven loss, retreating from near its 52-week high. Reported Dec '22 quarterly earnings -27% on +14% sales revenues versus the year ago period. Prior quarterly earnings increases have not been strong and steady above the +25% minimum guideline (C criteria).
2/28/2023 12:58:49 PM - Gapped down today for a big volume-driven loss, retreating from near its 52-week high. Reported Dec '22 quarterly earnings -27% on +14% sales revenues versus the yearago period. Prior quarterly earnings increases have not been strong and steady above the +25% minimum guideline (C criteria).
2/8/2023 11:33:16 AM - Perched at its 52-week high folllowing volume-driven gains. Reported Sep '22 quarterly earnings +29% on +28% sales revenues versus the yearago period. Prior quarterly earnings increases have not been strong and steady above the +25% minimum guideline (C criteria).
3/18/2019 12:30:06 PM - Pulled back below prior highs in the $106 area, slumping into the prior base. Encountering damaging distributional pressure with recent volume-driven losses. Negated most of the bullish action which had come after it reported earnings +138% on +21% sales revenues for the Dec '18 quarter. Prior mid-day reports noted - "Quarterly earnings increases have been above the +25% minimum guideline (C criteria) with sequential comparisons showing encouraging acceleration in its sales revenues growth rate. Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead."
3/15/2019 1:12:13 PM - Pulling back below prior highs in the $106 area, slumping into the prior base. Encountering damaging distributional pressure with recent volume-driven losses. Negated most of the bullish action which had come after it reported earnings +138% on +21% sales revenues for the Dec '18 quarter. Prior mid-day reports noted - "Quarterly earnings increases have been above the +25% minimum guideline (C criteria) with sequential comparisons showing encouraging acceleration in its sales revenues growth rate. Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead."
3/14/2019 1:18:07 PM - Pulling back from its all-time high, encountering distributional pressure with recent volume-driven losses. Bullish action had come after it reported earnings +138% on +21% sales revenues for the Dec '18 quarter, and prior mid-day reports noted - "Quarterly earnings increases have been above the +25% minimum guideline (C criteria) with sequential comparisons showing encouraging acceleration in its sales revenues growth rate. Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead."
3/13/2019 12:31:11 PM - Pulling back from its all-time high, encountering distributional pressure with recent volume-driven losses. Bullish action had come after it reported earnings +138% on +21% sales revenues for the Dec '18 quarter, and prior mid-day reports noted - "Quarterly earnings increases have been above the +25% minimum guideline (C criteria) with sequential comparisons showing encouraging acceleration in its sales revenues growth rate. Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead."
3/7/2019 12:47:58 PM - Perched near its all-time high, consolidating after considerable volume-driven gains. Bullish action came after it reported earnings +138% on +21% sales revenues for the Dec '18 quarter. Quarterly earnings increases have been above the +25% minimum guideline (C criteria) with sequential comparisons showing encouraging acceleration in its sales revenues growth rate. Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead.